Valuation: Keros Therapeutics, Inc.

Capitalization 547M 474M 445M 405M 743M 47.2B 841M 5.2B 2.03B 21.57B 2.05B 2.01B 79.32B P/E ratio 2025 *
47.7x
P/E ratio 2026 * -3.18x
Enterprise value 387M 336M 315M 286M 526M 33.39B 595M 3.68B 1.44B 15.25B 1.45B 1.42B 56.11B EV / Sales 2025 *
1.75x
EV / Sales 2026 * 31.7x
Free-Float
94.57%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.46%
1 week-4.47%
Current month-4.88%
1 month-4.34%
3 months+15.83%
6 months-30.69%
Current year-14.97%
More quotes
1 week 13.31
Extreme 13.31
14.04
1 month 13.31
Extreme 13.31
15.4
Current year 9.12
Extreme 9.12
16.7
1 year 9.12
Extreme 9.12
72.37
3 years 9.12
Extreme 9.12
73
5 years 9.12
Extreme 9.12
88.8
10 years 9.12
Extreme 9.12
88.8
More quotes
Manager TitleAgeSince
Chief Executive Officer 69 2015-11-30
President 51 2024-06-30
Director of Finance/CFO 55 2020-01-31
Director TitleAgeSince
Chairman 69 2024-06-30
Director/Board Member 62 2016-03-31
Chairman 52 2016-03-31
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.46%-4.47%-69.81%-52.99% 547M
-2.64%-1.69%-51.32%-8.60% 53.77B
-0.04%-7.95%+32.90%+50.89% 33.27B
-3.91%-3.67%+59.42%+89.93% 32.38B
+0.28%+6.97%+56.66%-28.41% 26.61B
-1.28%-3.67%+18.69%-18.72% 25.23B
-1.29%+41.88%+54.99%+478.98% 19.05B
-0.50%-7.93%+151.27%+1,915.23% 14.74B
-1.46%-4.92%-21.01%-24.21% 13.72B
-3.31%-4.42%+108.82%-61.86% 13.32B
Average -1.56%+1.73%+34.06%+234.03% 23.26B
Weighted average by Cap. -1.68%+1.30%+28.54%+168.01%
See all sector performances

Financials

2025 *2026 *
Net sales 221M 192M 180M 164M 300M 19.07B 340M 2.1B 820M 8.71B 829M 811M 32.04B 17.24M 14.96M 14.04M 12.77M 23.44M 1.49B 26.5M 164M 63.97M 680M 64.66M 63.31M 2.5B
Net income 11.69M 10.15M 9.52M 8.66M 15.9M 1.01B 17.98M 111M 43.4M 461M 43.87M 42.95M 1.7B -183M -159M -149M -136M -249M -15.83B -282M -1.74B -681M -7.23B -688M -674M -26.61B
Net Debt -160M -139M -130M -119M -218M -13.81B -246M -1.52B -594M -6.31B -600M -588M -23.22B -
More financial data * Estimated data
Logo Keros Therapeutics, Inc.
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its second product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Employees
163
More about the company
Date Price Change Volume
25-06-17 13.46 $ -1.46% 298,599
25-06-16 13.66 $ +0.74% 587,398
25-06-13 13.56 $ -0.59% 377,915
25-06-12 13.64 $ -1.09% 489,193
25-06-11 13.79 $ +0.29% 428,830

Delayed Quote Nasdaq, June 17, 2025 at 04:00 pm EDT

More quotes
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
13.46USD
Average target price
29.20USD
Spread / Average Target
+116.94%
Consensus

Quarterly revenue - Rate of surprise